The reasons for drug attrition have evolved over the years; over the last 25 years, lack of safety (both non-clinical and clinical) remains the major cause of attrition during clinical development, which accounts for approximately 20%–30% of all drug discontinuation (see Figure 16.1). 1–4 More worrying is the fact that there is no clear trend toward a reduction of the attrition owing to safety reasons.